Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 27,159 shares, a growth of 50.6% from the January 15th total of 18,035 shares. Based on an average daily trading volume, of 12,513 shares, the days-to-cover ratio is presently 2.2 days. Based on an average daily trading volume, of 12,513 shares, the days-to-cover ratio is presently 2.2 days.
Algernon Pharmaceuticals Price Performance
Algernon Pharmaceuticals stock opened at $0.04 on Friday. The stock’s 50 day moving average is $0.05 and its 200 day moving average is $0.05. Algernon Pharmaceuticals has a one year low of $0.03 and a one year high of $0.08.
Algernon Pharmaceuticals Company Profile
Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.
The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).
Read More
- Five stocks we like better than Algernon Pharmaceuticals
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
Receive News & Ratings for Algernon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Algernon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
